76143-20-9

Basic information

• Product Name: 5-formyl-2-hydroxybenzamide
• Synonyms: 5-formyl-2-hydroxybenzamide;BENZAMIDE, 5-FORMYL-2-HYDROXY-
• CAS NO: 76143-20-9
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.14608
• Mol File: 76143-20-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 204-206 °C(Solv: water (7732-18-5))
• Boiling Point: 335.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.396±0.06 g/cm3(Predicted)
• PKA: 6.18±0.18(Predicted)
• CAS DataBase Reference: 5-formyl-2-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-formyl-2-hydroxybenzamide(76143-20-9)
• EPA Substance Registry System: 5-formyl-2-hydroxybenzamide(76143-20-9)

Safety Data

• Hazardous Substances Data: 76143-20-9(Hazardous Substances Data)

Usage

General Description

5-formyl-2-hydroxybenzamide, also known as salicylaldehyde hydrazone, is an organic compound with the molecular formula C7H7NO2. It consists of a benzene ring with a hydroxyl group and a formyl group attached to it, as well as an amide functional group. 5-formyl-2-hydroxybenzamide is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its anti-inflammatory and antioxidant properties. Additionally, 5-formyl-2-hydroxybenzamide has been found to exhibit chelating properties, making it useful for complexing with metal ions in chemical analysis and as a potential treatment for metal poisoning.

Upstream product

• 41489-76-3 methyl-5-formyl-2-hydroxybenzoate 
• 32780-64-6 labetalol hydrochloride 
• 21962-50-5 5-formyl-2-methoxybenzonitrile 
• 34841-06-0 3-bromo-4-methoxybenzylaldehyde 
• 36894-69-6 labetaol 
• 125872-38-0 3-carbamoyl-4-methoxy-benzaldehyde 

Downstream Products

• 850256-41-6 doxaliform 
• 636595-43-2 N-(5-{4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-2,4-dioxo-imidazolidin-1-yl]but-2-ynyloxymethyl}-2-hydroxybenzamidomethyl)doxorubicin 
• 636595-71-6 4-[3-(2-{2-[2-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[e][1,3]oxazin-6-ylmethoxy)-ethoxy]-ethoxy}-ethyl)-4,4-dimethyl-2,5-dioxo-imidazolidin-1-yl]-2-trifluoromethyl-benzonitrile 
• 636595-68-1 4-(3-{2-[2-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[e][1,3]oxazin-6-ylmethoxy)-ethoxy]-ethyl}-4,4-dimethyl-2,5-dioxo-imidazolidin-1-yl)-2-trifluoromethyl-benzonitrile 
• 636595-74-9 4-{3-[4-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[e][1,3]oxazin-6-ylmethoxy)but-2-ynyl]-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl}-2-trifluoromethylbenzonitrile 
• 636595-81-8 5-{4-[3-(4-cyano-3-trifluoromethyl-phenyl)-5,5-dimethyl-2,4-dioxo-imidazolidin-1-yl]-but-2-ynyloxymethyl}-2-hydroxy-benzamide 
• 850256-37-0 doxorubicin-5-formylsalicylamide 
• 636595-50-1 2-hydroxy-5-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxymethyl}-benzamide 
• 636595-48-7 2-hydroxy-5-[2-(2-hydroxyethoxy)ethoxymethyl]benzamide 
• 636595-52-3 2-hydroxy-5-(4-hydroxy-but-2-ynyloxymethyl)-benzamide 
• 269411-78-1 2-benzyloxy-5-formyl-benzamide 

Relevant articles and documents

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

TARGETED DRUG-FORMALDEHYDE CONJUGATES AND METHODS OF MAKING AND USING THE SAME

The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacokinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.

Substituted benzamide inhibitors of rhinovirus 3C protease

Nonpeptide benzamide-containing inhibitors of human rhinovirus (HRV) 3C protease are described.